MS worsening without relapses varies by study rules

Credibility

Interest

Share:1 min read

Key Takeaway

The rate of MS worsening without relapses changed depending on how researchers defined and measured it.

What They Found

Researchers compared 360 ways to identify disability worsening that happened without a relapse. The ways they defined a starting point and confirmed worsening had a strong effect on the results. Depending on the rules, studies would find about 0.14 to 0.66 worsening events per decade. About 75% to 92% of those events lasted, depending on the rules used. Researchers proposed one set of rules to make future study results easier to compare.

Who Should Care and Why

The study used records from people with MS, most of whom had relapsing-remitting MS. Their records came from 186 centers across 43 countries. The study is about tracking disability worsening that occurs without a relapse. Different rules can give different rates, even when researchers study the same records. A shared set of rules could make results from future studies easier to compare.

Important Considerations

You should know this was an analysis of existing records from 33,303 people with MS. The proposed rules were chosen to balance how often worsening was found and how often it lasted. This study did not test whether those rules improve your care.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News